Clinical Trial Update: A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 multiple-dose trial of the investigational compound NNC 0151-0000-0000 in subjects with rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• NNC 0151-0000-0000

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Rheumatoid Arthritis | Phase 2 | Status: COMPLETED